Merck, Inc.
🇵🇭Philippines
Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)
Phase 1
Completed
- Conditions
- Atherosclerotic Vascular Disease
- Interventions
- Drug: atorvastatinDrug: placebo
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 83
- Registration Number
- NCT00703261
MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)
Phase 2
Terminated
- Conditions
- Metabolic X Syndrome Dyslipidemia
- Interventions
- Drug: MK0767
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 436
- Registration Number
- NCT00703690
Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00702715
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00701103
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00701389
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus, Non Insulin DependentDiabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1035
- Registration Number
- NCT00701090
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
Phase 1
Completed
- Conditions
- Herpes Zoster
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 290
- Registration Number
- NCT00696709
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
Phase 1
Completed
- Conditions
- Liver Insufficiency
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00696826
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00694083
Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)
Phase 1
Completed
- Conditions
- Neoplasm
- Interventions
- Biological: Dalotuzumab
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00694356
© Copyright 2025. All Rights Reserved by MedPath